* clinical signs of covid-19 indicative of impending hospitalization * documented infection in addition to covid-19 that requires systemic treatment * medical condition that could adversely impact safety, in the investigator's opinion * is or planning to be pregnant or lactating * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit * has received or will receive during study participation a vaccine for covid-19 * has participated in clinical trial protocols in the last 12 months, unless the investigator believes that there may be a direct benefit to the subject

* clinical signs of covid-19 indicative of impending hospitalization * documented infection in addition to covid-19 that requires systemic treatment * medical condition that could adversely impact safety, in the investigator's opinion * is or planning to be pregnant or lactating * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit * has received or will receive during study participation a vaccine for covid-19 * has participated in clinical trial protocols in the last 12 months, unless the investigator believes that there may be a direct benefit to the subject

- clinical signs of covid-19 indicative of impending hospitalization - documented infection in addition to covid-19 that requires systemic treatment - medical condition that could adversely impact safety, in the investigator's opinion - is or planning to be pregnant or lactating - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - has received or will receive during study participation a vaccine for covid-19 - has participated in clinical trial protocols in the last 12 months, unless the investigator believes that there may be a direct benefit to the subject

- clinical signs of covid-19 indicative of impending hospitalization - documented infection in addition to covid-19 that requires systemic treatment - medical condition that could adversely impact safety, in the investigator's opinion - is or planning to be pregnant or lactating - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit - has received or will receive during study participation a vaccine for covid-19 - has participated in clinical trial protocols in the last 12 months, unless the investigator believes that there may be a direct benefit to the subject